Search research articles
Contact Us
Filters
Showing results (321-330 of 344) with videos related to
Page
of 35
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
J W Riess, H A Yu, X Le, et al.
Eclinicalmedicine
|
May 1, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
G D Marijn Veerman, Rene J Boosman, Merel Jebbink, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 20, 2024
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer
Ilias Houda, Idris Bahce, Chris Dickhoff, et al.
Clinical Pharmacology and Therapeutics
|
May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment
Nikki de Rouw, Leila-Sophie Otten, Mart P Kicken, et al.
Cancer Communications (London, England)
|
May 25, 2026
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer
Daan A C Lanser, Niels Heersche, M Benthe Muntinghe-Wagenaar, et al.
Journal of the American Heart Association
|
August 5, 2021
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report
Emelia J Benjamin, Sana M Al-Khatib, Patrice Desvigne-Nickens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 1, 2024
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC
Niels Heersche, Daan A C Lanser, M Benthe Muntinghe-Wagenaar, et al.
BMC Cancer
|
June 17, 2020
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
Relinde I Y Lieverse, Evert J Van Limbergen, Cary J G Oberije, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2017
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer
A J van der Wekken, R Pelgrim, N 't Hart, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 30, 2015
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer
Wouter W Mellema, Lucie Masen-Poos, Egbert F Smit, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 344) with videos related to
Sort By:
Page
of 35
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
J W Riess, H A Yu, X Le, et al.
Eclinicalmedicine
|
May 1, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
G D Marijn Veerman, Rene J Boosman, Merel Jebbink, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 20, 2024
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer
Ilias Houda, Idris Bahce, Chris Dickhoff, et al.
Clinical Pharmacology and Therapeutics
|
May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment
Nikki de Rouw, Leila-Sophie Otten, Mart P Kicken, et al.
Cancer Communications (London, England)
|
May 25, 2026
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer
Daan A C Lanser, Niels Heersche, M Benthe Muntinghe-Wagenaar, et al.
Journal of the American Heart Association
|
August 5, 2021
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report
Emelia J Benjamin, Sana M Al-Khatib, Patrice Desvigne-Nickens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 1, 2024
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC
Niels Heersche, Daan A C Lanser, M Benthe Muntinghe-Wagenaar, et al.
BMC Cancer
|
June 17, 2020
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
Relinde I Y Lieverse, Evert J Van Limbergen, Cary J G Oberije, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2017
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer
A J van der Wekken, R Pelgrim, N 't Hart, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 30, 2015
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer
Wouter W Mellema, Lucie Masen-Poos, Egbert F Smit, et al.
Page
of 35